NeoImmuneTech (A950220) Q3 2024 earnings summary

Executive summary

• Focuses on T cell-based immunotherapy R&D, with NT-I7 as the lead candidate in oncology and non-oncology indications.

• No commercial product sales yet; revenue comes from research services and collaborations.

• Pipeline includes multiple clinical and preclinical programs targeting solid tumors, hematologic malignancies, and acute radiation syndrome.

• Holds exclusive rights to NT-I7 in major markets and maintains global partnerships for clinical development.

Financial highlights

• 2024 Q3 revenue: $806,272, all from research services.

• Operating loss for 2024 Q3: $(23,788,691); net loss: $(23,880,317).

• Cash and cash equivalents at Q3-end: $38.1 million.

• R&D expenses for 2024 Q3: $17.5 million (61% of total headcount in R&D).

• No dividend history; accumulated deficit continues to grow.

Outlook and guidance

• Expects continued high R&D spending as clinical trials progress.

• Focus on licensing out NT-I7 and advancing ARS therapy to commercialization.

• Ongoing efforts to secure additional partnerships and expand pipeline.